Pharma's top drugs in 2025, featuring Merck, BMS blockbusters by Eric Sagonowsky Friday, October 4, 2019 Humira has been topping pharma's sales charts, but in a few years it'll be passed by Keytruda and several other meds, a GlobalData forecast shows.
J&J's Darzalex makes history with 3rd OK in new myeloma patients by Angus Liu Friday, September 27, 2019 Darzalex has become the first biologic approved for newly diagnosed multiple myeloma patients who are eligible for stem cell transplant.
BeiGene hits back at allegations of faked sales numbers by Angus Liu Monday, September 9, 2019 BeiGene's shares slid about 15% on allegations that it artificially inflated sales of in-licensed Celgene cancer drugs, including Revlimid, by 60%.
The top 10 all-time biggest-selling drugs by 2024 by Angus Liu Thursday, August 15, 2019 New king Humira, fast-growing Revlimid, Roche's under-attack cancer cash cows. Here are the biopharma's most successful drugs by lifetime sales till 2024.
Celgene's Revlimid, Pomalyst leap ahead on new triple-combo OKs by Angus Liu Tuesday, July 30, 2019 Myeloma drugs Revlimid, Pomalyst and Otezla joined hands to deliver a strong quarter at Celgene.
Bristol bumps Lynch, recruits Novartis vet for post-merger team by Arlene Weintraub Wednesday, June 5, 2019 Bristol-Myers is counting on new talent from Novartis and Celgene—and a revamped R&D chart—to buck up its existing drugs and new launches.
Revlimid, Rituxan combo OK'd as chemo-free lymphoma regimen by Angus Liu Wednesday, May 29, 2019 The nod comes as Celgene and Roche are looking to add new indications to their old cancer stalwarts.
NICE grants Celgene long-awaited thumbs-up for Revlimid by Arlene Weintraub Friday, May 17, 2019 The new endorsement of Celgene's Revlimid from England's cost watchdog NICE may not help calm fears about BMS' $74 billion buyout.
